Popular Trials
Antimicrobial Peptide
Antimicrobial Peptide Spray for Diabetic Foot
Recruiting0 awardsPhase 2
La Jolla, California
This trial is testing the effectiveness and safety of a topical spray called Antimicrobial Peptide PL-5 in treating mild infections of diabetic foot ulcers. Participants will be randomly assigned to receive either the
Alkylating agents
Oral Azacitidine + R-miniCHOP for Diffuse Large B-Cell Lymphoma
Recruiting1 awardPhase 2 & 3
San Diego, California
This trial compares side effects & activity of azacitidine & R-miniCHOP (monoclonal antibody, prednisone, 3 chemo drugs) in 75+ newly-diagnosed DLBCL patients. Combining azacitidine & R-miniCHOP may shrink the cancer or extend time w/o symptoms/survival compared to R-miniCHOP alone.
BOS-589 for Irritable Bowel Syndrome
Recruiting0 awardsPhase 2
San Diego, California
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).
Behavioral Intervention
Self-Contained Underwater Breathing Apparatus (SCUBA) without OT +1 More for Depression Treatment
Recruiting1 award4 criteria
Loma Linda, California
The purpose of the study is to investigate whether an occupational therapy program could enhance mental health outcomes for veterans who SCUBA dive. SCUBA diving requires modified breathing techniques and has been found to provide calming effects to individuals who engage in this activity. Occupational therapy interventions such as mindfulness, journaling, and deep breathing techniques can also provide similar calming effects. Therefore, this study will explore whether occupational therapy can provide additional benefits to overall mental health of veterans who SCUBA dive.
GABA receptor modulator
SAGE-217 for Depression
Recruiting0 awardsPhase 2
Garden Grove, California
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.
Anti-viral
Sofosbuvir +2 More for Hepatitis
Recruiting4 awardsPhase 3
San Diego, California
This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in treatment-naive patients with Hepatitis C (HCV) genotype 2 or 3. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12). This was a non-inferiority study, and if non-inferiority was demonstrated, the study was then allowed to test for superiority.
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
Recruiting3 awardsPhase 3
San Diego, California
This trial will study the long-term effects of dupilumab, a drug used to treat atopic dermatitis, in adults. The trial will also assess the immunogenicity of dupilumab and monitor its efficacy. There is also an optional sub-study that will assess the safety of a new dupilumab drug product and evaluate its systemic exposure and immunogenicity.
Antiretroviral
E/C/F/TAF +1 More for Antiretroviral Therapy
Recruiting3 awardsPhase 3
San Diego, California
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin +2 More for Type 2 Diabetes
Recruiting3 awardsPhase 3
Vista, California
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Placebo for Joint Pain
Recruiting1 awardPhase 3
San Diego, California
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer. PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients with stage I, stage II, or stage III breast cancer receiving hormone therapy.
GW685698X aqueous nasal spray for Allergic Rhinitis
Recruiting4 awardsPhase 3
Long Beach, California
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.
Trials With No Placebo
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
Recruiting3 awardsPhase 3
San Diego, California
This trial will study the long-term effects of dupilumab, a drug used to treat atopic dermatitis, in adults. The trial will also assess the immunogenicity of dupilumab and monitor its efficacy. There is also an optional sub-study that will assess the safety of a new dupilumab drug product and evaluate its systemic exposure and immunogenicity.
Insulin
Insulin Glargine +1 More for Type 2 Diabetes
Recruiting5 awardsPhase 4
San Diego, California
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) \< 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents Secondary objectives of the comparative period (24 weeks): \>To assess the effect of insulin glargine in comparison with liraglutide on: * HbA1c level * Percentage of patients whose HbA1c has decreased but remains \>= 7% at the end of the comparative period * Percentage of patients whose HbA1c has increased at the end of the comparative period * Fasting Plasma Glucose (FPG) * 7-point Plasma Glucose (PG) profiles * Hypoglycemia occurrence * Body weight * Adverse events Objectives of the extension period (24 weeks): \>To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on: * HbA1c level * FPG * 7-point PG profiles * Hypoglycemia occurrence * Body weight * Adverse events
GW685698X aqueous nasal spray for Allergic Rhinitis
Recruiting4 awardsPhase 3
Long Beach, California
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.
Tyrosine Kinase Inhibitor
Lorlatinib for Liver Dysfunction
Recruiting1 awardPhase 1
Tustin, California
This trial tests Lorlatinib, a pill, in adults with different liver functions. Researchers will see how the medicine moves through the body and check for any side effects. Lorlatinib is approved for the treatment of a specific type of lung cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.